Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
We greatly appreciate the comment by Nousari and Anhalt concerning our article published in the ARCHIVES.
We agree with the authors that the final and optimal dosage of mycophenolate mofetil for the treatment of autoimmune diseases, such as pemphigus, still needs to be defined. The dosage of 2 g/d that we suggested may be too low to benefit certain patients with severe disease, although, in our hands, this dosage usually induced remissions.
Enk AH, Knop J. The Role of Mycophenolate Mofetil in the Management of Pemphigus—Reply. Arch Dermatol. 1999;135(7):854. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-7-dlt0799